Cardiol Therapeutics Inc. Class A Share Price

Cardiol Therapeutics Inc. Class A Share Price

NASDAQ: CRDL
$1.20
+$0.02 (1.70%) Last updated on 29 Oct, 2026 | 20:30 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Cardiol Therapeutics Inc. Class A Stock Performance

Open
$1.19
Prev. Close
$1.18
Circuit Range
N/A
Day Range
$1.19 - $1.21
Year Range
$0.88 - $2.34
Volume
6,053
Average Traded
$1.20

Cardiol Therapeutics Inc. Class A Share Price Today

As of 29 October 2026, Cardiol Therapeutics Inc. Class A's share price is $1.20. The stock opened at $1.19, compared to its previous close of $1.18. During today's trading session, Cardiol Therapeutics Inc. Class A's share price traded between $1.19 and $1.21, with an average price of $1.20. Over the past 52 weeks, the stock has recorded a high of $2.34 and a low of $0.88. In terms of performance, Cardiol Therapeutics Inc. Class A's share price has declined by 13.41% over the last six months and is up 5.75% on a year-on-year basis.

Cardiol Therapeutics Inc. Class A Share Price Chart

Line chart of the Cardiol Therapeutics Inc. Class A price trend over the selected period. The price rose overall, ranging from 1.19 to 1.21, ending at 1.20.
$1.19$1.21
L
Show Current Price
H

Cardiol Therapeutics Inc. Class A Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
N/A
EPS (TTM)
N/A
Revenue (TTM)
N/A
Return On Equity (TTM)
N/A
Profit Margin
N/A
Debt to Equity
N/A
Quarterly Earnings Growth YoY
N/A

About Cardiol Therapeutics Inc. Class A

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Cardiol Therapeutics Inc. Class A Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$1.64
$1.20
-28.23%
Sep 2026
$1.95
$1.67
-19.17%
Aug 2026
$1.23
$2.06
+63.49%
Jul 2026
$1.06
$1.26
+20.00%
Jun 2026
$1.24
$1.05
-13.93%
May 2026
$1.36
$1.22
-11.59%
Apr 2026
$1.39
$1.38
+1.85%
Mar 2026
$1.01
$1.35
+32.84%
Feb 2026
$0.94
$1.02
+7.37%
Jan 2026
$0.98
$0.95
-0.73%
Dec 2025
$1.10
$0.96
-8.42%
Nov 2025
$1.14
$1.04
-7.52%

CRDL Share Price FAQs